NASDAQ:BLFS - BioLife Solutions Stock Price, Forecast & News

BioLife Solutions trades on the NASDAQ under the ticker symbol "BLFS."

BioLife Solutions Inc (NASDAQ:BLFS) released its quarterly earnings results on Tuesday, November, 12th. The medical equipment provider reported $0.01 earnings per share for the quarter, hitting the Zacks' consensus estimate of $0.01. The medical equipment provider earned $6.60 million during the quarter, compared to analysts' expectations of $7.65 million. BioLife Solutions had a return on equity of 5.37% and a net margin of 46.77%. View BioLife Solutions' Earnings History.

BioLife Solutions is scheduled to release their next quarterly earnings announcement on Thursday, March 12th 2020. View Earnings Estimates for BioLife Solutions.

BioLife Solutions issued an update on its FY 2020 After-Hours earnings guidance on Monday, November, 25th. The company provided EPS guidance of for the period. The company issued revenue guidance of $$50-56 million, compared to the consensus revenue estimate of $$42.95 million.

5 brokerages have issued 12 month price targets for BioLife Solutions' shares. Their forecasts range from $22.00 to $26.00. On average, they anticipate BioLife Solutions' stock price to reach $23.80 in the next year. This suggests a possible upside of 46.8% from the stock's current price. View Analyst Price Targets for BioLife Solutions.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioLife Solutions in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BioLife Solutions.

News headlines about BLFS stock have been trending somewhat positive recently, according to InfoTrie. The research firm identifies positive and negative press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. BioLife Solutions earned a daily sentiment score of 0.7 on InfoTrie's scale. They also assigned press coverage about the medical equipment provider a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for BioLife Solutions.

BioLife Solutions saw a drop in short interest during the month of December. As of December 31st, there was short interest totalling 1,620,000 shares, a drop of 5.8% from the December 15th total of 1,720,000 shares. Based on an average trading volume of 144,600 shares, the days-to-cover ratio is currently 11.2 days. Approximately 10.7% of the company's stock are sold short. View BioLife Solutions' Current Options Chain.

Some companies that are related to BioLife Solutions include Natus Medical (NTUS), AxoGen (AXGN), Cutera (CUTR), TransMedics Group (TMDX), Zynex (ZYXI), Stereotaxis (STXS), Semler Scientific (SMLR), Viewray (VRAY), Rockwell Medical (RMTI), Fonar (FONR), Soleno Therapeutics (SLNO), BioSig Technologies (BSGM), Edap Tms (EDAP), Second Sight Medical Products (EYES) and IRIDEX (IRIX).

Based on aggregate information from My MarketBeat watchlists, some companies that other BioLife Solutions investors own include Canopy Growth (CGC), Twilio (TWLO), Cara Therapeutics (CARA), Micron Technology (MU), Progenics Pharmaceuticals (PGNX), AbbVie (ABBV), Amarin (AMRN), Roku (ROKU), Verastem (VSTM) and Alibaba Group (BABA).

BioLife Solutions' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Roubaix Capital LLC (0.68%), Penbrook Management LLC (0.13%) and Mesirow Financial Investment Management Inc. (0.12%). Company insiders that own BioLife Solutions stock include Andrew G Hinson, Casdin Partners Master Fund, L, Greef Roderick De, James Mathers, Johan Wedell-Wedellsborg, Joseph C Schick, Michael Rice, Raymond W Cohen, Thomas Girschweiler, Todd Berard and Walter Villiger. View Institutional Ownership Trends for BioLife Solutions.

BLFS stock was sold by a variety of institutional investors in the last quarter, including Penbrook Management LLC and Mesirow Financial Investment Management Inc.. Company insiders that have sold BioLife Solutions company stock in the last year include Andrew G Hinson, Greef Roderick De, James Mathers, Johan Wedell-Wedellsborg, Joseph C Schick, Michael Rice, Raymond W Cohen, Todd Berard and Walter Villiger. View Insider Buying and Selling for BioLife Solutions.

BLFS stock was purchased by a variety of institutional investors in the last quarter, including Roubaix Capital LLC. View Insider Buying and Selling for BioLife Solutions.

Shares of BLFS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of BLFS stock can currently be purchased for approximately $16.21.

BioLife Solutions has a market capitalization of $331.53 million and generates $19.74 million in revenue each year. The medical equipment provider earns $3.27 million in net income (profit) each year or $0.14 on an earnings per share basis. BioLife Solutions employs 54 workers across the globe.View Additional Information About BioLife Solutions.

The official website for BioLife Solutions is http://www.biolifesolutions.com/.

BioLife Solutions' mailing address is 3303 MONTE VILLA PARKWAY SUITE 310, BOTHELL WA, 98021. The medical equipment provider can be reached via phone at 425-402-1400 or via email at [email protected]